These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 9579425)

  • 21. ras gene activation and infrequent mutation in papillary serous carcinoma of the peritoneum.
    Garrett AP; Ng SW; Muto MG; Welch WR; Bell DA; Berkowitz RS; Mok SC
    Gynecol Oncol; 2000 Apr; 77(1):105-11. PubMed ID: 10739698
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Genetic evidence for the multicentric origin of synchronous multiple gastric carcinoma.
    Kang GH; Kim CJ; Kim WH; Kang YK; Kim HO; Kim YI
    Lab Invest; 1997 Mar; 76(3):407-17. PubMed ID: 9121123
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Allelic imbalance and mutations of the PTEN gene in ovarian cancer.
    Saito M; Okamoto A; Kohno T; Takakura S; Shinozaki H; Isonishi S; Yasuhara T; Yoshimura T; Ohtake Y; Ochiai K; Yokota J; Tanaka T
    Int J Cancer; 2000 Jan; 85(2):160-5. PubMed ID: 10629071
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Microsatellite instability and p53 mutations in therapy-related leukemia suggest mutator phenotype.
    Ben-Yehuda D; Krichevsky S; Caspi O; Rund D; Polliack A; Abeliovich D; Zelig O; Yahalom V; Paltiel O; Or R; Peretz T; Ben-Neriah S; Yehuda O; Rachmilewitz EA
    Blood; 1996 Dec; 88(11):4296-303. PubMed ID: 8943866
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Genetic analysis of benign ovarian tumors.
    Thomas NA; Neville PJ; Baxter SW; Campbell IG
    Int J Cancer; 2003 Jul; 105(4):499-505. PubMed ID: 12712441
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A molecular genetic and statistical approach for the diagnosis of dual-site cancers.
    Brinkmann D; Ryan A; Ayhan A; McCluggage WG; Feakins R; Santibanez-Koref MF; Mein CA; Gayther SA; Jacobs IJ
    J Natl Cancer Inst; 2004 Oct; 96(19):1441-6. PubMed ID: 15467033
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evidence for common clonal origin of multifocal lung cancers.
    Wang X; Wang M; MacLennan GT; Abdul-Karim FW; Eble JN; Jones TD; Olobatuyi F; Eisenberg R; Cummings OW; Zhang S; Lopez-Beltran A; Montironi R; Zheng S; Lin H; Davidson DD; Cheng L
    J Natl Cancer Inst; 2009 Apr; 101(8):560-70. PubMed ID: 19351924
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Determination of clonal origin of recurrent hepatocellular carcinoma for personalized therapy and outcomes evaluation: a new strategy for hepatic surgery.
    Wang B; Xia CY; Lau WY; Lu XY; Dong H; Yu WL; Jin GZ; Cong WM; Wu MC
    J Am Coll Surg; 2013 Dec; 217(6):1054-62. PubMed ID: 24246620
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Application of clonal analysis. Differential diagnosis for synchronous primary ovarian and endometrial cancers and metastatic cancer.
    Fujita M; Enomoto T; Wada H; Inoue M; Okudaira Y; Shroyer KR
    Am J Clin Pathol; 1996 Mar; 105(3):350-9. PubMed ID: 8602617
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparative analysis of loss of heterozygosity of specific chromosome 3, 13, 17, and X loci and TP53 mutations in human epithelial ovarian cancer.
    Manderson EN; Presneau N; Provencher D; Mes-Masson AM; Tonin PN
    Mol Carcinog; 2002 Jun; 34(2):78-90. PubMed ID: 12112314
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ovarian cancer has frequent loss of heterozygosity at chromosome 12p12.3-13.1 (region of TEL and Kip1 loci) and chromosome 12q23-ter: evidence for two new tumour-suppressor genes.
    Hatta Y; Takeuchi S; Yokota J; Koeffler HP
    Br J Cancer; 1997; 75(9):1256-62. PubMed ID: 9155043
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Detection of cellular heterogeneity by DNA ploidy, 17 chromosome, and p53 gene in primary carcinoma and metastasis in a case of ovarian cancer.
    Calugi A; Eleuteri P; Cavallo D; Naso G; Albonici L; Lombardi MP; Manzari V; Romanini C; DeVita R
    Int J Gynecol Pathol; 1996 Jan; 15(1):77-81. PubMed ID: 8852451
    [TBL] [Abstract][Full Text] [Related]  

  • 33. p53 gene status and response to platinum/paclitaxel-based chemotherapy in advanced ovarian carcinoma.
    Lavarino C; Pilotti S; Oggionni M; Gatti L; Perego P; Bresciani G; Pierotti MA; Scambia G; Ferrandina G; Fagotti A; Mangioni C; Lucchini V; Vecchione F; Bolis G; Scarfone G; Zunino F
    J Clin Oncol; 2000 Dec; 18(23):3936-45. PubMed ID: 11099323
    [TBL] [Abstract][Full Text] [Related]  

  • 34. p53 allelotypes and enhanced detection of allelic loss in ovarian cancer: lack of correlation with familial and clinical factors.
    Skilling JS; Powills K; Lager DJ; Anderson B; Sorosky J; Buller RE
    Gynecol Oncol; 1996 May; 61(2):180-8. PubMed ID: 8626130
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Detailed genetic and physical mapping of tumor suppressor loci on chromosome 3p in ovarian cancer.
    Fullwood P; Marchini S; Rader JS; Martinez A; Macartney D; Broggini M; Morelli C; Barbanti-Brodano G; Maher ER; Latif F
    Cancer Res; 1999 Sep; 59(18):4662-7. PubMed ID: 10493522
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Molecular genetic evidence for monoclonal origin of bilateral ovarian serous borderline tumors.
    Sieben NL; Kolkman-Uljee SM; Flanagan AM; le Cessie S; Cleton-Jansen AM; Cornelisse CJ; Fleuren GJ
    Am J Pathol; 2003 Apr; 162(4):1095-101. PubMed ID: 12651602
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Microsatellite instability differences between familial and sporadic ovarian cancers.
    Arzimanoglou II; Lallas T; Osborne M; Barber H; Gilbert F
    Carcinogenesis; 1996 Sep; 17(9):1799-804. PubMed ID: 8824498
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A missense mutation in the BRCA2 gene in three siblings with ovarian cancer.
    Roth S; Kristo P; Auranen A; Shayehgi M; Seal S; Collins N; Barfoot R; Rahman N; Klemi PJ; Grénman S; Sarantaus L; Nevanlinna H; Butzow R; Ashworth A; Stratton MR; Aaltonen LA
    Br J Cancer; 1998 Apr; 77(8):1199-202. PubMed ID: 9579822
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Loss of heterozygosity, microsatellite instability and TP53 gene status in ovarian carcinomas.
    Plisiecka-Hałasa J; Dansonka-Mieszkowska A; Kraszewska E; Dańska-Bidzińska A; Kupryjańczyk J
    Anticancer Res; 2008; 28(2A):989-96. PubMed ID: 18507046
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Loss of heterozygosity on the X chromosome is an independent prognostic factor in ovarian carcinoma: from the Danish "MALOVA" Ovarian Carcinoma Study.
    Høgdall EV; Ryan A; Kjaer SK; Blaakaer J; Christensen L; Bock JE; Glud E; Jacobs IJ; Høgdall CK
    Cancer; 2004 Jun; 100(11):2387-95. PubMed ID: 15160342
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.